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Targeting a phospho-STAT3-
miRNAs pathway improves 
vesicular hepatic steatosis in an  
in vitro and in vivo model
Laura Belloni1, Silvia Di Cocco2,3, Francesca Guerrieri1, Abigail D. G. Nunn1, Silvia Piconese2,4, 
Debora Salerno1, Barbara Testoni5, Claudio Pulito6, Federica Mori6, Matteo Pallocca7, 
Andrea Sacconi8, Elisa Vivoli9, Fabio Marra9, Sabrina Strano6,10, Giovanni Blandino8, 
Massimo Levrero1,2,5,11 & Natalia Pediconi1,3
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease. Although genetic 
predisposition and epigenetic factors contribute to the development of NAFLD, our understanding 
of the molecular mechanism involved in the pathogenesis of the disease is still emerging. Here we 
investigated a possible role of a microRNAs-STAT3 pathway in the induction of hepatic steatosis. 
Differentiated HepaRG cells treated with the fatty acid sodium oleate (fatty dHepaRG) recapitulated 
features of liver vesicular steatosis and activated a cell-autonomous inflammatory response, inducing 
STAT3-Tyrosine-phosphorylation. With a genome-wide approach (Chromatin Immunoprecipitation 
Sequencing), many phospho-STAT3 binding sites were identified in fatty dHepaRG cells and several 
STAT3 and/or NAFLD-regulated microRNAs showed increased expression levels, including miR-
21. Innovative CARS (Coherent Anti-Stokes Raman Scattering) microscopy revealed that chemical 
inhibition of STAT3 activity decreased lipid accumulation and deregulated STAT3-responsive 
microRNAs, including miR-21, in lipid overloaded dHepaRG cells. We were able to show in vivo that 
reducing phospho-STAT3-miR-21 levels in C57/BL6 mice liver, by long-term treatment with metformin, 
protected mice from aging-dependent hepatic vesicular steatosis. Our results identified a microRNAs-
phosphoSTAT3 pathway involved in the development of hepatic steatosis, which may represent a 
molecular marker for both diagnosis and therapeutic targeting.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries1. The 
excessive accumulation of triglyceride-containing lipid droplets (LD) within hepatocytes in NAFLD patients is a 
potentially reversible process, that may evolve into a severe necro-inflammatory form called non-alcoholic steato-
hepatitis (NASH), which can eventually lead to cirrhosis and hepatocarcinoma (HCC)2,3. Genetic and epigenetic 
factors together with multiple risk factors (i.e. obesity, insulin resistance, type-2-diabetes, elevated glucose, hyper-
lipidemia) have been described to promote liver injury1,4. Intrahepatic activation of pro-inflammatory signaling, 
such as the IL6/STAT3 pathway, plays a significant role in the development of chronic liver diseases. STAT3 is con-
stitutively activated in HCC by phosphorylation of Tyr705 and Ser727, resulting in STAT3 dimerization, nuclear 
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translocation, DNA binding and gene transcription5,6. IL6/STAT3-dependent molecular mechanisms driving 
hepatic steatosis and the pathological processes that cause NAFLD progression are still poorly understood3,7.
MicroRNAs (miRNAs) are a class of noncoding endogenous RNAs that regulate gene expression and specific 
miRNA expression profiles are strongly associated with several pathological conditions, including NAFLD8,9. 
There is a growing body of evidence demonstrating that miRNAs are closely associated with the IL6/STAT3 sign-
aling pathway, supporting the existence of regulatory feedback loops between expression of specific miRNAs and 
the STAT3 pathway in HCC and other diseases10,11.
The present study investigates the role of a miRNAs-phospho-STAT3 pathway in the induction of liver vesic-
ular steatosis in an in vitro model, represented by hepatic differentiated HepaRG cells treated with sodium oleate, 
fatty dHepaRG. Indeed, lipid overloaded dHepaRG cells showed typical features of mature hepatocytes, as we 
observed by CARS (Coherent Anti-stokes Raman Scattering) microscopy, an innovative technique that ena-
bles lipid droplets visualization and quantification without labeling, by probing their characteristic vibrational 
properties12.
We identified by Chromatin Immunoprecipitation Sequencing that phospho-STAT3, which is activated in 
fatty dHepaRG, is able to bind and regulate several miRNAs after lipid overload. Our results showed for the first 
time that suppression of the miRNAs-phospho-STAT3 pathway by S3I-201, a STAT3 specific inhibitor, decreased 
hepatic lipid accumulation. We have also observed in vivo that reducing both phospho-STAT3 and miR-21 lev-
els in C57BL6 mice liver, by long-term treatment with metformin, a widely used anti-diabetic drug, strongly 
improved age dependent hepatic steatosis. Activation of a new miRNAs-phospho-STAT3 pathway that is involved 
in the development of hepatic steatosis may represent a target for novel therapeutic strategies and might also have 
potential as a biomarker for diagnosis.
Results
Sodium oleate treatment of dHepaRG cells induced lipid droplets accumulation, ROS genera-
tion and deregulated lipid metabolism and liver-specific genes expression. Human HepaRG cells 
exposed to 2% DMSO are able to differentiate into hepatocyte-like and biliary-like phenotypes and possess the 
ability to stably express liver-specific genes such as Albumin, AldolaseB, CYP2E1 and CYP3A4 (Supplementary 
1a/b). Treatment of differentiated HepaRG cells (dHepaRG) with the fatty acid sodium oleate 250 μM for 2 or 4 
days (Supplementary 1c) led to generation of cytoplasmic lipid droplets detected by Oil Red O staining (Fig. 1a), 
strongly increasing the cellular lipid content, as demonstrated by FACS analysis with Bodipy, a neutral lipid 
marker (Fig. 1b), and inducing cellular reactive oxygen species (ROS) generation, quantified by FACS analysis 
after 2′,7′-dichlorodihydrofluorescein diacetate (DHCFDA) staining (Fig. 1c). Since accumulation of triglycerides 
and ROS plays an important role in inducing hepatocyte injury associated with NAFLD13, we decided to inves-
tigate whether the effect of lipid droplets and ROS generation were able to trigger gene expression modulation 
in dHepaRG cells. We performed a qPCR analysis of sodium oleate 250 μM treated dHepaRG transcripts using a 
Human Fatty Liver Array (Sabiosciences), that profiles the expression of 84 key genes involved in the mechanisms 
of NAFLD and hepatic insulin resistance (Supplementary Table 1). We observed that several genes were signif-
icantly deregulated after treatment (Supplementary Fig. 2a/c). We showed in Fig. 1d (dark columns) that genes 
involved in carbohydrate (PDK4), cholesterol (ABCA1, APOB) or other lipid metabolism (ACSL5) were upreg-
ulated together with beta-oxidation genes (CPT1A) and insulin signaling pathway genes (FOXA2, PIK3CA). 
Interestingly, the glucose transporters (SLC2A1, SLC2A2, SLC2A4) and the fatty acid transport protein SLC27A5 
were strongly reduced by sodium oleate treatment, together with the fatty acid biosynthesis gene SCD (Fig. 1d, 
dark grey columns). Moreover, key genes involved in the inflammatory response (IL6, NFKB1) and in the adi-
pokine signaling pathway (SERPINE1, MTOR) were upregulated in response to lipid overload (Fig. 1d, light grey 
columns). These results demonstrated that sodium oleate treated human dHepaRG cells showed typical features 
of vesicular steatosis associated with a deregulation of gene expression.
Fatty dHepaRG activate a cell autonomous IL6 inflammatory response. To investigate the role 
of the inflammatory response in the pathogenesis of vesicular steatosis, we analyzed a TaqMan Low Density 
Array (TLDA Cards) which profiles the expression of 96 key genes involved in the Interferon signaling path-
way (Supplementary Table 1). We found deregulation of many genes after sodium oleate 250 μM treatment 
(Supplementary Fig. 2b/c), including upregulation of USP18, OAS1, ISG15 and IL8 transcripts (Fig. 2a). We 
could also observe an increase at the protein level of the inflammatory genes Serpine1, USP18 and IL1-b cytokine, 
activated by the inflammasome response (Fig. 2b), and an accumulation of the secreted cytokine IL6 (Fig. 2c). 
Interestingly, we observed that fatty dHepaRG cells did not activate a canonical NF-kB inflammatory pathway. 
Indeed, as demonstrated by Immunoblot analysis of nuclear and cytoplasmic protein extracts, NF-kB/p65 did not 
translocate into nuclei of sodium oleate treated cells (Fig. 2d).
In order to assess if the observed IL6 accumulation lead to the activation of the JAK/STAT signaling, we evalu-
ated phosphorylation levels of the down stream mediators of the pathway. After sodium oleate 250 μM treatment, 
STAT3-Tyr705 and JAK2 phosphorylation levels were significantly higher as compared to control cells, (Fig. 3a), 
whereas Ser727 phosphorylation of STAT3 and total STAT3 protein levels remained unchanged (Fig. 3a); STAT3 
transcripts levels were also not affected (Fig. 3b). IL6/JAK2 pathway and ROS signaling are both described as 
STAT3 activators via Tyr705 phosphorylation6,13. To study whether these pathways are involved in STAT3 sodium 
oleate dependent Tyr705 phosphorylation, we treated cells with Ruxolitinib 1 μM, an inhibitor of JAK1/2 tyros-
ine kinases, and with the ROS inhibitor NAC 10 mM (N-acetylcysteine). We tested Ruxolitinib 1μM and NAC 
10 mM activity by IL6 ELISA assay and DHCFDA FACS quantification, respectively (Supplementary Fig. 3a/b). 
We showed that Ruxolitinib was able to strongly reduce phospho-Tyr-STAT3 levels in both dHepaRG cells treated 
with sodium oleate 250 μM and control cells (Fig. 3c). Conversely, treatment with NAC 10 mM did not show any 
effect on both sodium oleate 250 μM and control phospho-Tyr-STAT3 levels (Fig. 3d). Taken together, these 
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results indicated that fatty dHepaRG activate a cell-autonomous inflammatory response via STAT3-Tyr705 phos-
phorylation regulated by the IL6/JAK cascade, but not by the oxidative stress signaling.
Identification of phospho-STAT3 target genes in fatty dHepaRG by a genome wide 
approach. In order to identify, at a genome-wide level, genes potentially regulated by phospho-STAT3 during 
the pathogenesis of steatosis, we performed a Chromatin Immunoprecipitation Sequencing (ChIP-seq) analysis 
on fatty dHepaRG cells using a phosphoTyr705-STAT3-specific antibody. Raw data for ChIP-seq are available 
at GEO (GSE89157). Results indicated 82883 total peaks, corresponding to phospho-STAT3 candidate bind-
ing sites, in control dHepaRG cells (Ctrl) and 184946 in sodium oleate 250 μM treated dHepaRG cells, which 
Figure 1. Sodium oleate treatment of dHepaRG cells induced lipid droplets accumulation, ROS formation 
and deregulated lipid metabolism and liver-specific genes expression. (a) Differentiated HepaRG (dHepaRG) 
cells were treated with vehicle (control) or with sodium oleate 250 μM for 2 or 4 days. After treatments, cells 
were stained with Oil Red O, lipid droplets are visible in red (Upper panels). Oil Red O dye was eluted and 
OD measured at 500 nm. Results are expressed as fold change of treated cells over control (Lower panel). 
(b) dHepaRG cells treated as in (a) were analyzed by citofluorimetry after Bodipy staining. Left panel: 
representative overlay of profile. Right panel: Histograms show MFI (Mean Fluorescence Intensity) as fold 
induction of treated cells over control from 3 independent experiments. (c) dHepaRG cells treated as in (a) 
were analyzed by citofluorimetry after DHCFDA (2′,7′-dichlorodihydrofluorescein diacetate) dye staining. 
Left panel: representative overlay of profile. Right panel: Histograms show % of DHCFDA positive cells as fold 
induction of treated cells over control from 3 independent experiments. (d) dHepaRG cells were treated as in (a) 
for 4 days. cDNAs were analyzed with a Human Fatty Liver RT² Profiler PCR Array, histograms show expression 
levels of a selected panel of genes as fold induction of treated cells over control. (Bars indicate S.D.; asterisks 
indicate p-value).
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partially overlapped with the control peaks (51332 peaks); among the 184946 peaks in sodium oleate treated 
dHepaRG cells we found a significant amount of phospho-STAT3 bindings specifically induced by sodium oleate 
(132994 Oleate-specific) (Fig. 4a). Motif enrichment analysis associated to ChIP-Seq peaks identified STAT and 
IRF (interferon-regulatory factor) transcription factors putative binding sites (Fig. 4b). Automatically scanning 
for phospho-STAT3 binding sites revealed that several miRNAs promoters are bound in sodium oleate-treated 
cells, including miR-21 (Fig. 4c left panel) and miR-122 (Supplementary Fig. 4). Moreover, phospho-STAT3 
has been found also on promoters of several metabolic and inflammatory genes, including ISG15 (Fig. 4d left 
panel), PLIN4 and USP18 (Supplementary Fig. 4). To validate these results, we performed an independent ChIp 
assay against acetylated-Histone4 and phosphoTyr705-STAT3 in dHepaRG cells treated with sodium oleate. As 
shown in Fig. 4c,d (right panels), we confirmed phospho-STAT3 enrichment on miR-21 and ISG15 promoters in 
response to lipid accumulation, which paralleled with increased acetylation levels of bound Histone-4, a marker 
of transcriptional active chromatin. Overall, these results showed that phoshpo-STAT3 is induced to bind a panel 
of genes and miRNAs in fatty dHepaRG cells, suggesting a role in the pathogenesis of liver steatosis.
A STAT3-microRNA signaling is activated during lipid accumulation. We selected a panel of known 
STAT3-related miRNAs and miRNAs deregulated in NAFLD/NASH, as shown in Table 1. We observed that 
dHepaRG sodium oleate (250 μM) dependent lipid accumulation led to a differential expression of the selected 
hepatic/STAT3-responsive miRNAs (Fig. 4a): in particular, a significant increase of miR-21, miR-181-b, miR-
18a and miR-34a levels (Fig. 5a upper panel, black columns) and a significant downregulation of miR-26a, let7a, 
miR-122, and miR-221 (Fig. 5a lower panel, black columns). To study the role of STAT3 in the regulation of these 
miRNAs we treated dHepaRG cells with a STAT3 inhibitor, S3I-201, which targets STAT3 DNA-binding and tran-
scriptional activities14. We tested S3I-201 inhibitory activity by IL6 ELISA assay and qPCR mRNA levels quan-
tification of a known STAT3-transcritpional target HP (Haptoglobin) (Supplementary Fig. 5a/b). Interestingly, 
co-treatment with sodium oleate 250 μM and with S3I-201 100 μM, was able to significantly reduce sodium oleate 
dependent upregulation of miR-21, miR-181-b, miR-18a expression (Fig. 5a upper panel, dark grey columns), 
partially restored miR-122 expression and strongly increased let7a levels (Fig. 5a lower panel, dark grey columns). 
These results demonstrated that phospho-STAT3 regulates the expression levels of a panel of miRNAs, including 
miR-21, in response to lipid accumulation. We focused on miR-21 for its emerging role in lipid metabolism and 
recent observations of increased expression in hepatocellular carcinoma and in NAFLD patients15–17. To confirm 
a direct role of STAT3 on miR-21 transcription we demonstrated that pri-miR-21 expression level correlates with 
mature-miR-21 regulation (Supplementary Fig. 5c).
To investigate in vivo miR-21 expression levels in a mouse model of liver steatosis, we took advantage of 
C57/BL6 mice fed a High-Fat diet (HFD). HFD mice showed typical features of NAFLD/NASH, with increased 
ALT (alanine aminotransferase) liver enzyme activity levels, body weight and glucose levels as compared to mice 
Figure 2. Fatty dHepaRG cells activate a cell autonomous IL6 inflammatory response. (a) dHepaRG cells 
were treated with vehicle (Ctrl) or with sodium oleate 250 μM for 4 days. cDNAs were analyzed by qPCR 
with primers specific for the indicated genes and normalized to Actin. (b) Left panel: total protein extracts 
were analyzed by Immunoblotting with the indicated antibodies. Right panel: densitometric analysis (ImageJ 
software). (c) Cells were treated as in a) and supernatants were colllected to quantify secreted IL6 levels by 
ELISA assay. (d) Left panel: nuclear and cytoplasmic protein extracts from cells treated as in a) were analysed 
by Immunoblotting with the indicated antibodies. Right panel: densitometric analysis (ImageJ software). 
Histograms show fold induction of treated cells versus control; bars indicate S.D.; asterisks indicate p-value. 
Full-length blots are included in Supplementary Fig. 9.
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fed normal diet (ND) (Supplementary Fig. 6a–d). We observed that miR-21 was overexpressed also in HFD mice 
liver as compared to ND mice (Fig. 5b, upper panel) and phospho-STAT3 protein levels are upregulated (Fig. 5b, 
lower panel and Supplementary Fig. 6e).
STAT3 inhibition reduced dHepaRG sodium oleate-dependent lipid accumulation. In addition 
to transcriptionally regulating a panel of miRNAs, we investigated whether STAT3 activation could be directly 
involved in the induction of vesicular steatosis. By FACS analysis after Bodipy staining, we showed that inhibition 
of STAT3 activity with S3I-201 100 μM strongly reduced lipid accumulation in sodium oleate 250 μM co-treated 
dHepaRG cells as compared to the sodium oleate treatment alone (Fig. 6a). Similar results were observed after 
co-treatment with Ruxolitinib 1 μM, which inhibits STAT3 phosphorylation and slightly but significantly reduced 
Bodipy MFI (Supplementary Fig. 7a). Conversely, inhibition of ROS generation by co-treatment with NAC 
10 mM did not affect lipid accumulation induced by sodium oleate 250 μM (Supplementary Fig. 7b). Moreover, 
we showed that STAT3 inhibition by S3I-201 reverted oleate dependent up-regulation of lipid metabolism genes, 
analysed by qPCR (Supplementary Fig. 7c). To further characterize the role of STAT3 in lipid droplets genera-
tion we made use of the nonlinear Coherent Anti-Stokes Raman Scattering (CARS) microscopy18,19. Treatment 
with sodium oleate 250 μM induced a significant increase in the number of LD (Fig. 6b), which led to a higher 
total droplets area per cell (Fig. 6c, left panel), but an unchanged mean LD area (Fig. 6c, right panel), indicating 
that after oleate treatment LD increase in number but not in dimension. Interestingly, co-treatment with STAT3 
inhibitor S3I-201, dramatically decreased sodium oleate induced LD number (Fig. 6b) and total LD area per cell 
(Fig. 6c, left panel), whereas it slightly decreased mean LD area (Fig. 6c, right panel).
Figure 3. Activation of STAT3 in fatty dHepaRG. (a) Left panel: dHepaRG cells were treated with vehicle (Ctrl) 
or with sodium oleate 250 μM for 4 days, protein extracts were analyzed by immunoblotting with the indicated 
antibodies. Right panel: densitometric analysis (ImageJ software). (b) RNA transcripts were extracted from 
cells treated as in a) and cDNAs were analyzed with STAT3 specific primers and normalized to Actin. (c/d) 
dHepaRG cells were treated with vehicle (Ctrl) or with sodium oleate 250 μM for 4 days, and co-treated for the 
subsequent 18 hours with sodium oleate 250 μM and with Ruxolitinib 1 μM (c) or with sodium oleate 250 μM 
and NAC 10 mM (d). Left panels: protein extracts were analyzed by Immunoblot with the indicated antibodies. 
Right panels: densitometric analysis (ImageJ software). Histograms show relative protein level expressed as 
fold induction of treated cells versus control; bars indicate S.D.; asterisks indicate p-value. Full-length blots are 
included in Supplementary Fig. 10.
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Therefore, these results strongly demonstrate that STAT3 activation directly contributes to lipid accumulation 
and LD generation and is able to drive transcription of several metabolism genes.
Inhibition of phospho-STAT3 and miR-21 expression by metformin long-term therapy pro-
tected mice against age dependent liver steatosis. To evaluate STAT3 and miR21 implication in 
liver steatosis also in vivo, we treated 5 weeks aged C57/BL6 mice for 72 weeks with metformin, an established 
anti-diabetic drug, that is able to modulate STAT3 signaling by repressing IL-6-dependent phosphorylation 
of STAT320,21. At sacrifice, 77 weeks old control mice (H2O treated) showed an evident macro-vesicular liver 
steatosis due to aging, with well-defined fat droplets occupying the cytoplasm of hepatocytes (Fig. 7a, pan-
els C,D) as compared to samples collected from young 5 weeks old mice (Fig. 7a panels A,B). Interestingly, 
metformin-treated mice showed a significantly attenuated liver steatosis (Fig. 7a panels E,F) as compared to 
control mice (H2O) (Fig. 7a, panels C,D). Moreover, metformin treatment reduced mice body weight (Fig. 7b) 
Figure 4. Identification of phospho-STAT3 binding sites in fatty dHepaRG by ChIP-seq analysis. 
dHepaRG cells were treated with sodium oleate 250 μM for 4 days (Oleate) or vehicle treated (Ctrl) and 
immunoprecipitated with a phospho-Tyr705-STAT3 specific antibody. (a) Candidate phospho-STAT3 binding 
sites from MACS2 peak calling (default MACS2 parameters, qvalue < 0.01). (b) Motif enrichment analysis: 
STAT (signal transducer and activator of transcription), IRF (interferon-regulatory factor). (c/d) Chip-seq 
profile (left panels) showing phospho-STAT3 enrichment (black circles) on miR-21 (c) and ISG15 (d) promoters 
after sodium oleate 250 μM treatment. Right panels: cross-linked chromatin from dHepaRG cells treated as 
in (a) was immunoprecipitated with a phosphoTyr705-STAT3 (pSTAT3) and an acetylated-Histone4 (AcH4) 
antibody and analyzed by qPCR with primers specific for the observated phospho-STAT3 peaks on miR-21 
(c) and ISG15 (d) promoters, identified by chipseq analysis as shown in left panels. Histograms show Fold 
Induction (FI) of the % of Input (mean from 3 independent experiments; bars indicate S.D.; asterisks indicate 
p-value).
Upregulated 
miRNAs
Downregulated 
miRNAs References
NAFLD/NASH miR-18a, miR-21, miR-34a, miR-122
miR-26a, miR-
122, miR-221
Pirola C. J., et al.6; 
Gerhard G. S.8
STAT3 miR-21, miR-18a Cao Q.
10; Jin K.11; 
Iliopoulos D.31
Table 1. NAFLD/NASH and/or STAT3 regulated miRNA.
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and decreased number of phospho-STAT3 positive hepatocyte cells in mice liver (Fig. 7c, left panel), as shown 
by Immunohistochemistry, with an average of 63.8% in control mice (H2O) versus only 23.8% in metformin 
treated mice (Fig. 7c, right panel). In addition, miR-21 levels were significantly downregulated in liver tissue from 
mice treated with metformin as compared to control and young 5weeks mice (Fig. 7d) and also in mice serum 
(Supplementary Fig. 8), paralleling phospho-STAT3 expression levels.
These results demonstrate that downregulation of both phospho-STAT3 and miR-21 levels in the liver after 
long-term treatment with metformin improves age-dependent macro-vesicular liver steatosis in mice.
Discussion
NAFLD is a complex disease trait whose development and progression are determined by the combination of 
genetic and epigenetic changes1,4,8,9. NAFLD and NASH are associated with substantial metabolic stress and 
inflammation, mediated by IL6/STAT3 signaling, that affects both cell survival and determine an increased risk 
of developing hepatocellular carcinoma3,6,22.
The present study demonstrates the activation of the IL6-STAT3 axis in an in vitro model of vesicular steatosis, 
with consequent de-regulation of several STAT3-related miRNAs. Human hepatic HepaRG cell line, a valuable 
alternative to primary human hepatocytes, has been used as a model of vesicular steatosis23. Indeed, we already 
showed that addition of sodium oleate to differentiated HepaRG cells induces lipid storage in droplets, that were 
statistically quantified in terms of numbers, distribution and morphology at single cell level, utilizing a new 
label-free microscopy technique, coherent anti-Stokes Raman scattering (CARS)12. CARS microscopy it is now 
recognized as a powerful non-invasiveness tool for the investigation of biological specimens, as it is capable of 
imaging unstained living cells with a high vibrational sensitivity and chemical selectivity18,19.
Here, we demonstrated that lipid overloaded dHepaRG cells induced the activation of an intracellular auton-
omous inflammatory response, with increased STAT3-Tyr705 phosphorylation levels. Contrarily, STAT3-Ser727 
phosphorylation, which also enhances STAT3 transcriptional efficacy, but it is not mandatory for STAT3 activa-
tion24, was not modulated. We found by Chip-seq using an antibody that specifically recognizes phosphoryla-
tion at specific Tyrosine 705 residue, that phospho-STAT3-Tyr705 is able to differentially bind many promoters, 
including miR-21 regulatory region, after the induction of vesicular steatosis in dHepaRG cells (raw data for 
ChIP-seq are available at GEO GSE89157). Lipid overloading-dependent activation of STAT3 is directly responsi-
ble for the transcriptional modulation of miR-21 and several other miRNAs. Indeed, we were able to show for the 
Figure 5. A STAT3-microRNA signaling is involved in lipid accumulation. (a) dHepaRG cells were treated 
with sodium oleate 250 μM for 4 days or vehicle treated (Ctrl) and co-treated for the subsequent 48 hours 
with sodium oleate 250 μM plus S3I-201 100 μM or S3I-201 alone. Total RNA were extracted and miRNAs 
levels were analyzed by qPCR (TaqMan MicroRNA Assay, Applied Biosystems), samples were normalized to 
the RNU38B endogenous control. Histograms show mean value expressed as fold induction of treated versus 
control cells. (b) C5BL6 mice were fed a high-fat diet (HFD) or normal diet (ND) for 16 weeks. Upper panel: 
total RNA were extracted from mice liver and q-PCR quantification of miR-21 expression was normalized 
to the snoRNA234 endogenous control. Lower panel: densitometric analysis (ImageJ software) of pSTAT3 
protein levels from liver mice total protein extracts analyzed by immunoblotting. Histograms show mean 
value expressed as fold induction of HFD samples versus ND samples. (Bars indicate S.D.; asterisks indicate 
p-value). Immunoblot is available in Supplementary Fig. 6e.
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first time that inhibition of STAT3 activity deregulates miRNA expression and in parallel improved steatohepatitis 
in vitro and in vivo, reducing neutral lipid accumulation and droplets generation, suggesting STAT3 as a potential 
therapeutic target for NAFLD.
No drug is currently available as a specific treatment for NAFLD and the combination of diet and lifestyle 
modifications remain the pillars of NAFLD and NASH management25,26. Nevertheless, it has been shown that 
metformin has anti-oxidant, anti-inflammatory and anti-fibrogenic properties in liver diseases and induces 
reduction in tissue lipid storage with an increase in both fatty acid oxidation and inhibition of lipogenesis, pre-
sumably mediated by AMPK activation27–29. Moreover, metformin is able to induce alterations in STAT3 signaling 
in many cell types20,21. However, metformin-induced activation of energy metabolism, via the energy-sensor 
AMPK, may not account for all benefit effects of the drug on NAFLD and the exact molecular mechanisms of its 
therapeutic action remain obscure27,29. Here, we have been able to show that reduction of STAT3 activation and 
miR-21 levels in C57/BL6 mice liver, by metformin long-term treatment (72 weeks), strongly ameliorated steato-
hepatitis that spontaneously occurred in control mice due to aging.
Altogether, the results we obtained in vitro and in vivo converge to indicate that miR-21 is involved in NAFLD 
pathogenesis. Indeed, it has been recently shown, in mice fed a high-fat diet, that liver-specific miR-21 knock-
out prevents steatosis by altering the expression of several master metabolic regulators30, and in a model of 
NASH-associated liver damage, miR-21 knockout mice display reduced steatosis, inflammation and lipoapop-
tosis, with impairment of fibrosis15. MiR-21 is overexpressed in many human cancers and is thought to play a 
significant role in carcinogenesis31,32. Circulating and liver tissue miR-21 level are also significantly increased 
in patients suffering from NASH and in inflammatory states of fatty liver disease15–17. However, the mechanism 
by which miR-21 might contribute to NASH/NAFLD development is still unknown. Bio-informatic prediction 
of miR-21 potential mRNAs target revealed putative genes involved in both HCC and in Fatty Liver disease 
(Table 2), including PTEN33, and SLC2A1 and PPARA that also showed reduced expression after sodium oleate 
treatment in dHepaRG cells (Fig. 1d). This analysis suggests a role for miR21 in fine tuning metabolic processes 
in hepatocytes by regulating gene expression at the post-transcriptional level.
In conclusion, here we described for the first time an integrated signaling module that links liver steatosis 
and the activation of IL6/STAT3 signaling with downstream STAT3-dependent activation of a number of miR-
NAs, including the onco-mir miR-21. STAT3 activation is responsible for the inflammatory micro-environment 
that facilitates lipid accumulation leading to the dysregulation of several miRNAs. The observation that 
down-regulating by metformin the activation of STAT3 and the overexpression of miR-21 in vivo limited lipid 
accumulation and liver damage identifies miR-21 and STAT3 inhibition as new promising pharmacological tar-
gets for treating NAFLD. Indeed, even though in pilot studies metformin was shown to improve fatty liver disease 
in mouse models of NAFLD34, as well as in NAFLD/NASH patients28,29, American guidelines do not recommend 
metformin for the treatment of adult NAFLD27.
On the other hand, several small molecules that indirectly inhibit STAT3 activation, by targeting the bind-
ing of cytokines and growth factors to their receptors, have been developed and some of them are currently 
Figure 6. STAT3 inhibition reduced dHepaRG sodium oleate-dependent lipid accumulation. (a) FACS analysis 
of dHepaRG cells treated as in Fig. 5(a) and stained with the Bodipy lipid probe. Histograms show fold change 
of treated samples over controls of Mean Bodipy Fluorescent Intensity (MFI). (b) CARS analysis of dHepaRG 
cells treated as in Fig. 5(a). Left panels: representative images showing lipid droplets fluorescence in red. Right 
panel: histogram shows mean number of LD, bars show S.E. (c) CARS analysis of dHepaRG cells treated as 
in Fig. 5(a), histograms show total droplet area/cell (left) and mean droplet area (right). (Bars indicate S.E.; 
asterisks indicate p-value).
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undergoing clinical application to treat human diseases, including cancer35. Nevertheless, these agents have sub-
optimal potency and pharmacokinetic parameters, and/or poorly defined mechanisms, including S3I-20136. A 
number of direct STAT3 inhibitors molecules have been developed to treat cancer and other human diseases, but 
are currently at preclinical stage35,37. Therefore, directly targeting STAT3 still remains an important aim to reduce 
off-target effects for clinical application, potentially including NAFLD management.
Figure 7. Inhibition of phospho-STAT3 and miR-21 expression by metformin long-term therapy protected 
mice against age dependent liver steatosis. (a) 5 weeks aged C57/BL6 mice were daily treated with either 
water or metformin (50 mpk) for 72 weeks. At the end of treatment (77 weeks) FFPE livers were stained with 
Hematoxylin/Eosin. Images A-B: 5 weeks aged mice before treatment; images C-D: 77 weeks old control mice 
(H20); images E-F: 77 weeks old mice metformin treated. (b) Dot plot showing body weight of mice treated as 
in (a). (c) Phospho-STAT3 immunohistochemistry (IHC) on liver sections of mice treated as in (a). Left panels: 
positive IHC cells are stained brown color, images A-B control mice (H20); images C-D metformin treated mice. 
Right panel: % number of phospho-STAT3 positive cells (6 fields for 4 non-consecutive stained sections per 
sample were scored). d) Boxplot representing q-PCR quantification of miR-21 expression in liver tissue from 
77 weeks mice treated as in (a) (H20 and Metformin) and 5 weeks mice (young) at the beginning of treatment. 
SnoRNA202 was used as endogenous control to standardize miRNAs expression. Results are expressed as 10−DCt 
(Asterisks indicate p-value).
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Material and Methods
Cell Culture and treatments. Human hepatic HepaRG cells were seeded at low density in William’s E 
medium with GlutaMAX (Gibco), supplemented with 10% FBS (Hyclone II GE), 1% penicillin/streptomycin 
(Sigma), 5 µg/mL insulin (Sigma), 0.5 µM hydrocortisone hemisuccinate (Sigma). After 1 week at confluence, 
cells were shifted into the same medium supplemented with 50 µM hydrocortisone hemisuccinate and 2% DMSO 
(Sigma) for 2 more weeks to obtain confluent differentiated cultures. Cells were then treated with different drugs 
(Supplementary Fig. 1c) for the indicated time at the following final concentrations: sodium oleate 250 μM 
(Sigma); S3I-201 100 μM alias NSC74859 (Selleckchem.); N-acetylcisteina 10 mM (Sigma); Ruxolitinib 1 μM 
(Selleckchem.). Cytoxicity of compounds was tested by MTT assay (Supplementary methods and Supplementary 
Fig. 1d).
Animal model. C57/BL6 mice were chronically treated with either water or metformin (50 mpk) for 72 
weeks (7 mice per group) (Fig. 7), or they were fed with either normal diet or with a High-Fat Diet (59% fat, 
15% protein, 26% carbohydrate) for 16 weeks (7 mice per group) (Fig. 5b). At the end of the study, livers from 
metformin treated mice were fixed in buffered formalin and embedded in paraffin, while livers from HFD fed 
mice were nitrogen frozen. Information about animal conditions are described in Supplementary methods. All 
methods were carried out in accordance with relevant guidelines and regulations and all experimental protocols 
were approved by the Italian Ministry of Health.
Immunohistochemistry. 5 μm-thick sections were trimmed from each FFPE histological specimen, and 
stained with Haematoxylin/Eosin and with phospho-STAT3 (Tyr705) (XP Cell Signaling, #9145) antibody as 
described in Supplementary methods.
FACS analysis. To quantify lipid accumulation Bodipy dye (Sigma) was used (100 nmol/L, 40′, 37 °C, excita-
tion/emission wavelengths 505/515 nm). 2′,7′-Dichlorofluorescin diacetate (DHCFDA) dye (Sigma) was used 
to monitor intracellular ROS production (10 μmol/L, 20′, 37 °C, excitation/emission wavelengths 488/520 nm). 
Cytofluorimetric analysis was performed using a FACS-CANTO (BD).
ELISA assay. The expression levels of interleukin 6 (IL6) secreted from sodium oleate treated dHepaRG cells 
were detected by enzyme-linked immunosorbent assay, IL6 ELISA, from Abcam (Ab 46042). Cell culture media 
was centrifuged at 1,000 g for 10 minutes to remove debris and supernatants were collected to perform standard 
ELISA as manufacturer’s protocol.
RNA and miRNAs extraction and analysis. See Supplementary methods.
Immunoblotting. Cells were lysed in NET buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.1% NP-40, 1 mM 
EDTA pH 8) and immunoblotted with the following antibodies: anti-STAT3 (#9139), anti-phospho-STAT3(-
Tyr705) (#9131), anti-phospho-STAT3(Ser727) (#9134), anti-IL1β (#12242), anti-phospho-JAK2(Tyr1007/1008) 
(#3771), anti-PAI-1 (D9C4) (#11907) from Cell Signaling; anti-NFκB p65 (sc-372), anti-USP18 (sc-98431) and 
anti-Actin (sc-1616) from Santa Cruz Biotechnology. Proteins of interest were detected with HRP-conjugated 
anti-mouse/rabbit/goat IgG antibodies from Santa Cruz Biotechnology and visualized with the Pierce ECL 
Western blotting substrate (ThermoScientific), according to the provided protocol. Autoradiography images were 
developed with a KODAK MIN-R processor. Full-length blots are included in Supplementary Figures 9/10.
ChIP and ChIPseq. Chromatin from dHepaRG cells was immuno-precipitated with the following antibod-
ies: anti-phospho-STAT3-Tyr705 (XP Cell Signaling, #9145), anti-tetra-acetylated-histone-H4-Lys-6-9-13-17 
(06-866 Upstate) and non-specific IgG (Santa Cruz Biotechnology Inc.). Chromatine Immunoprecipitated was 
analyzed by qPCR using fluorescent dye SYBR Green in a Light Cycler 480 instrument (Roche Diagnostics). Deep 
sequencing analysis38,39 was performed as described in Supplementary methods.
CARS microscopy. A multimodal nonlinear microscope was used to record images in formaldehyde fixed 
dHepaRG cells, using the strong methylene vibration at 2840 cm−1 as coherent Raman image contrast for lipids, 
as well as multiphoton auto-fluorescence contrast, as described in Supplementary methods. All data generated by 
CARS are included in Supplementary Table 2.
Statistics. P-values were determined using the 2-tailed Student’s T-test: *0,01 ≤ P < 0,05; **0,001 ≤ P < 0,01; 
***P < 0,001.
HCC HCC and FATTY LIVER FATTY LIVER
AKT2, BASP1, BCL2, CCL20, CCNG1, CCR1, CCR7, CD47, 
CDC25A, CDK6, CLOCK, EDIL3, EGFR, ERBB2, FANCC, 
FAS, FASLG, FGF18, FUBP1, IL12A, IL1B, JAG1, KLK10, LIFR, 
MATN2, MEF2A, MEF2C, MMP2, MMP9, MSH2, MTAP, MUC1, 
MYC, NCOA3, NFKB1, PARP1, PDCD4, PER3, PIK3C2A, 
PIK3R1, PTEN, PTK2, RB1, RDH11, RPL36A, RTN4, SKP2, 
SLC2A1, SP1, SPDYA, SPRY2, STAT3, TGFBI, TGFBR3, TIAM1, 
TP53BP2, TP63, WNT5A
E2F1, ICAM1, PPARA, TGFB1, 
VEGFA
CLOCK, EIF2S1, LUM, 
TNFRSF11B
Table 2. In silico analisys of miR-21 predicted target genes in HCC and Fatty Liver disease (mirwalk2.0).
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Data Availability
The datasets generated by Chipseq and analysed during the current study are available in the GEO repository data 
(GSE89157).
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